Y-mAbs Therapeutics Statistics
Total Valuation
YMAB has a market cap or net worth of $212.89 million. The enterprise value is $153.18 million.
Important Dates
The next estimated earnings date is Monday, August 11, 2025, before market open.
| Earnings Date | Aug 11, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
YMAB has 45.30 million shares outstanding. The number of shares has increased by 2.26% in one year.
| Current Share Class | 45.30M |
| Shares Outstanding | 45.30M |
| Shares Change (YoY) | +2.26% |
| Shares Change (QoQ) | +0.51% |
| Owned by Insiders (%) | 1.52% |
| Owned by Institutions (%) | 42.19% |
| Float | 25.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.33 |
| Forward PS | 2.52 |
| PB Ratio | 2.34 |
| P/TBV Ratio | 2.44 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.73 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.77, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.77 |
| Quick Ratio | 4.12 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -29.93% and return on invested capital (ROIC) is -15.64%.
| Return on Equity (ROE) | -29.93% |
| Return on Assets (ROA) | -12.62% |
| Return on Invested Capital (ROIC) | -15.64% |
| Return on Capital Employed (ROCE) | -25.43% |
| Revenue Per Employee | $852,481 |
| Profits Per Employee | -$271,471 |
| Employee Count | 104 |
| Asset Turnover | 0.75 |
| Inventory Turnover | 1.96 |
Taxes
| Income Tax | -301,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.93% in the last 52 weeks. The beta is 0.51, so YMAB's price volatility has been lower than the market average.
| Beta (5Y) | 0.51 |
| 52-Week Price Change | -60.93% |
| 50-Day Moving Average | 4.47 |
| 200-Day Moving Average | 8.01 |
| Relative Strength Index (RSI) | 49.79 |
| Average Volume (20 Days) | 219,882 |
Short Selling Information
The latest short interest is 2.65 million, so 5.86% of the outstanding shares have been sold short.
| Short Interest | 2.65M |
| Short Previous Month | 2.69M |
| Short % of Shares Out | 5.86% |
| Short % of Float | 10.60% |
| Short Ratio (days to cover) | 12.94 |
Income Statement
In the last 12 months, YMAB had revenue of $88.66 million and -$28.23 million in losses. Loss per share was -$0.63.
| Revenue | 88.66M |
| Gross Profit | 72.55M |
| Operating Income | -23.82M |
| Pretax Income | -23.97M |
| Net Income | -28.23M |
| EBITDA | -23.37M |
| EBIT | -23.82M |
| Loss Per Share | -$0.63 |
Full Income StatementBalance Sheet
The company has $60.31 million in cash and $603,000 in debt, giving a net cash position of $59.71 million or $1.32 per share.
| Cash & Cash Equivalents | 60.31M |
| Total Debt | 603,000 |
| Net Cash | 59.71M |
| Net Cash Per Share | $1.32 |
| Equity (Book Value) | 89.46M |
| Book Value Per Share | 1.98 |
| Working Capital | 71.49M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$19.15 million and capital expenditures -$127,000, giving a free cash flow of -$19.28 million.
| Operating Cash Flow | -19.15M |
| Capital Expenditures | -127,000 |
| Free Cash Flow | -19.28M |
| FCF Per Share | -$0.43 |
Full Cash Flow StatementMargins
Gross margin is 81.83%, with operating and profit margins of -26.87% and -31.84%.
| Gross Margin | 81.83% |
| Operating Margin | -26.87% |
| Pretax Margin | -32.18% |
| Profit Margin | -31.84% |
| EBITDA Margin | -26.36% |
| EBIT Margin | -26.87% |
| FCF Margin | n/a |
Dividends & Yields
YMAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.26% |
| Shareholder Yield | -2.26% |
| Earnings Yield | -13.26% |
| FCF Yield | -9.05% |
Analyst Forecast
The average price target for YMAB is $17.55, which is 273.40% higher than the current price. The consensus rating is "Buy".
| Price Target | $17.55 |
| Price Target Difference | 273.40% |
| Analyst Consensus | Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 18.56% |
| EPS Growth Forecast (5Y) | -5.69% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
YMAB has an Altman Z-Score of 7.5 and a Piotroski F-Score of 2.
| Altman Z-Score | 7.5 |
| Piotroski F-Score | 2 |
